Shareholders approve option repricing to $1.50; CTAD presentations set for Dec 1-4

Inmune Bio, Inc.

Special meeting approves repricing of up to 5,511,000 outstanding stock options for employees, execs, and directors to $1.50 per share.
Voting results: 7,144,433 for, 2,926,973 against, 121,836 abstentions.
Repricing effective Nov 18; exercise price set at closing price of $1.50 on Nasdaq that day.
Two presentations at CTAD conference Dec 1-4: Phase 2 MINDFuL trial results for XPro1595 in early Alzheimer’s, and EMACC validation.
Phase 2 trial data on selective soluble TNF neutralizer XPro1595 to be presented as a poster.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.